Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Amgen
Neonc Technologies, Inc.
Essen Biotech
Var2 Pharmaceuticals
Novartis
Dana-Farber Cancer Institute
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Telix Pharmaceuticals (Innovations) Pty Limited
Columbia University
Shandong Cancer Hospital and Institute
Stanford University
Universidade Federal de Pernambuco
Aminex Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
University of Florida
Quadriga Biosciences, Inc.
Weill Medical College of Cornell University
Gilead Sciences
Hospices Civils de Lyon
Shenzhen BinDeBio Ltd.
University Hospital Tuebingen
Shenzhen BinDeBio Ltd.
Maastricht Radiation Oncology
Ohio State University Comprehensive Cancer Center
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
Shenzhen Second People's Hospital
University of Arizona
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, San Francisco
INSYS Therapeutics Inc
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
NYU Langone Health
Case Comprehensive Cancer Center
Pharmacyclics LLC.